Bladder Cancer
Bladder CANCER
PD-L1
Testing is available to clinicians in order to guide treatment options in immunotherapy.
Bladder EpiCheck provides patients and clinicians with a simple urine test to detect recurrence of bladder tumours. The test analyses subtle disease-specific changes in DNA methylation markers, allowing for the detection of 92%1 of the high-risk (non-Ta-LG) cancers.
Further information
For more detail on screening and early cancer detection, please visit our Cancer Testing page.
For more detail on tests to investigate cancer aggressiveness or to guide treatment, please visit the Companion Diagnostics page.
USEFUL DOWNLOADS
ACCESS
If you are a healthcare professional, please contact us. If you are a patient, please refer your healthcare professional to our website and ask them to get in touch. Please note that Cambridge Clinical Laboratories HCP services are only available through a professional healthcare provider.
If you would like to use one of these services, please contact us.